How much funding has Myeloid Therapeutics raised?

Myeloid Therapeutics has raised $257.0M in total funding, most recently a Series B round.

Who are Myeloid Therapeutics's investors?

Myeloid Therapeutics's investors include ARCH Venture Partners, Newpath Management, Hatteras Venture Partners, Alexandria Venture Investments.

When was Myeloid Therapeutics founded?

Myeloid Therapeutics was founded in 2021.

Where is Myeloid Therapeutics headquartered?

Myeloid Therapeutics is headquartered in Cambridge, Massachusetts, United States.

What industry is Myeloid Therapeutics in?

Myeloid Therapeutics operates in Biotech.

How many employees does Myeloid Therapeutics have?

Myeloid Therapeutics has 11-50 employees.

Myeloid Therapeutics

formerly CREATE Medicines

Create Medicines | In Vivo Immune Programming with RNA-CAR Therapies

Cambridge, United States · Founded 2021 · $257.0M raised

Biotech

Headquarters: Cambridge, Massachusetts
Employees: 11–50
Founded: 2021
Business Model: B2B

Website: createmedicines.com
Total Funding: $257.0M
Last Round: $122.0M Series BMay 2026
Rounds: 4

About

Myeloid Therapeutics (rebranded as CREATE Medicines in October 2025) was a clinical-stage biotech pioneering in vivo immune programming using mRNA-LNP technology. Its platform engineers T cells, NK cells, and myeloid cells directly inside the body, enabling repeat-dose CAR therapies without ex vivo manufacturing.

Summary

Myeloid Therapeutics is a Biotech company based in Cambridge, United States, founded in 2021. It has raised $257.0M in total across 4 rounds, most recently a $122.0M Series B round in May 2026. Investors include ARCH Venture Partners, Newpath Management and Hatteras Venture Partners.

LinkedIn X (Twitter)